Company Cybin Inc.

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2025-07-18 pm EDT			5-day change	1st Jan Change
8.320 ^USD	-1.65%		+8.90%	-5.67%

Jul. 17	Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder	CI
Jul. 17	Cybin Says UK Regulator Approves Start of Second Phase 3 Trial for Experimental Adjunctive Treatment for Major Depressive Disorder	MT

Business description: Cybin Inc.

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Number of employees: 50

Sales by Activity: Cybin Inc.

Fiscal Period: March	2021	2022	2023	2024	2025

See all business segments

Executive Committee: Cybin Inc.

Manager	Title	Age	Since
Paul Glavine COO	Chief Operating Officer	36	2016-10-12
Eric So PSD	President	50	2020-11-04
Douglas Drysdale CEO	Chief Executive Officer	55	2020-07-31
Greg Cavers DFI	Director of Finance/CFO	55	2020-11-04
Aaron Bartlone COO	Chief Operating Officer	-	2023-06-30

See CYBIN INC. governance

Composition of the Board of Directors: Cybin Inc.

Director	Title	Age	Since
Eric So CHM	Chairman	50	2020-11-04
Paul Glavine BRD	Director/Board Member	36	2016-10-12
Eric Hoskins BRD	Director/Board Member	64	2020-11-04
Mark Lawson BRD	Director/Board Member	53	2020-11-04
Grant Froese BRD	Director/Board Member	63	2020-11-04
Theresa Firestone BRD	Director/Board Member	69	2021-08-15
George Tziras BRD	Director/Board Member	44	2023-10-22

Composition of the Board of Directors

Shareholders: Cybin Inc.

Name	Equities	%	Valuation
Tang Capital Management LLC 8.704 %	1,830,097	8.704 %	15 M $
Tang Capital Management LLC 8.704 %	1,830,097	8.704 %	15 M $
Deep Track Capital LP 7.277 %	1,530,000	7.277 %	13 M $
Deep Track Capital LP 7.276 %	1,529,987	7.276 %	13 M $
Point72 Asset Management LP 6.307 %	1,326,185	6.307 %	11 M $

List of CYBIN INC. shareholders

Company details: Cybin Inc.

Cybin, Inc.

100 King Street West Suite 5600

M5X 1C9, Toronto

http://www.cybin.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CYBIN INC.	-1.65%	+8.90%	-27.02%	-62.87%	192M
ARGENX SE	+0.24%	+2.39%	+15.57%	+35.09%	35.09B
WUXI APPTEC CO., LTD.	+1.95%	+7.06%	+110.02%	-19.87%	32.89B
BIONTECH SE	-0.92%	-2.54%	+27.38%	-31.68%	27.09B
SUMMIT THERAPEUTICS INC.	-5.18%	+4.80%	+168.72%	+2,260.36%	19.46B
INSMED INCORPORATED	-1.55%	+4.46%	+36.63%	+353.38%	19.48B
AKESO, INC.	+0.86%	+24.29%	+249.57%	+515.75%	16.09B
WUXI BIOLOGICS (CAYMAN) INC.	+0.88%	+7.13%	+154.00%	-62.61%	14.8B
GENMAB A/S	-0.07%	+3.01%	-23.33%	-44.07%	13.63B
EXELIXIS, INC.	-0.89%	-0.87%	+97.12%	+106.17%	12.13B
Average	-0.63%	+5.99%	+80.87%	+304.97%	19.09B
Weighted average by Cap.	-0.36%	+4.79%	+84.11%	+307.21%